HSA Expands Global Regulatory Pathways
Browse below ⤵
These initiatives kickstarts 2026 with a strong expanded regulatory access, shortened approval timelines, and promoted convergence with trusted authorities.
The recent partnerships with the UK, Malaysia and Hong Kong mark a significant shift toward coordinated reviews, reliance models and regulatory cooperation, benefiting innovators and patients alike.
Innovation breakthrough therapies
Existing
Access consortium
Added
UK MHRA bilateral review
Closer ties with HongKong
Existing
HK recongises Singapore
for medical device and therapeutic products
Added
Stronger collaboration in pharmaceuticals, medical
devices, advanced therapy
products and
traditional medicines.
Also, tobacco products
and vaping devices.
Medical Device
Existing
Thailand, Australia, Hong Kong, Philippines, Sri Lanka
Added
Malaysia pilot phase